Acurx pharmaceuticals announces presentation of ibezapolstat phase 2 clinical trial results at escmid global 2024 scientific conference

Staten island, n.y. , may 2, 2024 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat phase 2 clinical trial in patients with c.
ACXP Ratings Summary
ACXP Quant Ranking